Research & Development
Four companies pursue virtual cells differently – perturbation, modular, lab-in-loop, patient data – transforming drug discovery efficiency.
Four organizations pursue distinct virtual cell strategies: Xaira emphasizes perturbational data, CZI builds modular foundations, Recursion integrates lab-in-loop validation, Noetik starts with patient tissue for drug discovery.
Senior Indegene executive discusses why pharma R&D organizations of the future will need to be agile, modular and AI-native by design. Industry pilots are pointing the way to potential one click regulatory submissions.
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.